We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Isoform of Vascular Endothelial Cell Growth Inhibitor (VEGI<sub>72–251</sub>) Increases Interleukin-2 Production by Activation of T Lymphocytes.
- Authors
Jing-Juan Yao; Min Zhang; Xiao-Hui Miao; Ping Zhao; Zhu, Shi-Ying; Ding, Hui; Zhong-Tian Qi
- Abstract
The objective of this study is to investigate the characteristics of the recombinant variant of human vascular endothelial cell growth inhibitor, VEGI72–251, and compare its biological activities with that of its prototype VEGI24–174. The recombinant plasmid containing the variant VEGI72–251 gene was constructed and expressed in Escherichia coli. The effects of the expressed VEGI72–251 on cell proliferations were checked in the human umbilical vein endothelial cell line and certain tumor cell lines (ECV304 and B16). The inhibition of VEGI72–251 on angiogenesis was detected in the chorioallantoic membrane of chick embryos. In comparison with VEGI24–174, the recombinant human VEGI72–251 seems to have no effect on the proliferation of endothelial cells and the angiogenesis of the chorioallantoic membrane in vitro. An enzyme-linked immunosorbent assay-based method was used for the measurement of interleukin-2 (IL-2) production by peripheral blood monocytes (PBMCs) treated with VEGI72–251. PBMCs were pretreated with VEGI72–251 (1.25–12.50 μg/ml) for 24 h in vitro, and the IL-2 concentration in PBMC medium was increased from 354 pg/ml to 1256 pg/ml. It can be concluded that VEGI72–251 is able to increase the level of human IL-2 production by the activation of T lymphocytes. Differing from VEGI24–174 on anti-angiogenesis, VEGI72–251 may serve as an anti-cancer factor through its activation of T lymphocytes. Edited by Yuan-Chang YAN
- Publication
Acta Biochimica et Biophysica Sinica, 2006, Vol 38, Issue 4, p249
- ISSN
1672-9145
- Publication type
Academic Journal
- DOI
10.1111/j.1745-7270.2006.00155.x